|
| NARRATIVE REVIEW |
|
| Year : 2015 | Volume
: 61
| Issue : 2 | Page : 101-108 |
Heart failure: Novel therapeutic approaches
C Patel, S Deoghare
Department of Pharmacology, Government Medical College, Surat, Gujarat, India
Correspondence Address:
C Patel
Department of Pharmacology, Government Medical College, Surat, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.153104
Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorders that impairs the ability of the ventricle to fill with or eject blood. Despite effective medical interventions, mortality and morbidity remain substantial. There have been significant advances in the therapy of HF in recent decades, such as the introduction of beta-blockers and antagonists of the renin-angiotensin system but still there is a major unmet need for better therapies for HF. In the present era, pathophysiology of HF has been explored. Various novel pathways, molecular sites have been identified, which contribute to the progression of the disease. By targeting these sites, newer pharmacological agents have been developed, which can play a promising role in the treatment of HF. This article focuses on recent advancements in pharmacotherapy of HF, which include agents targeting myocardial contractility, cytokines and inflammation, fibrosis and remodeling, myocardial metabolism, oxidative stress, and other newly defined pathways.
[FULL TEXT] [PDF]*
|
